Stockreport

Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics [Yahoo! Fi...

Kairos Pharma, Ltd.  (KAPA) 
PDF LOS ANGELES, March 02, 2026 BUSINESS WIRE )--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeu [Read more]